Dual-targeted bioengineered bacterial extracellular vesicles has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 6, 2026: “Engineered bacterial particles reduced bone loss in older mice”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1 papers on dual-targeted bioengineered bacterial extracellular vesicles
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
Studies of dual-targeted bioengineered bacterial extracellular vesicles measured 2 outcomes; the most studied are osteogenic differentiation (1 study) and pathological bone loss (1).
osteogenic differentiation
upin mice1
Dual-targeted bioengineered bacterial extracellular vesicles increase osteogenic differentiation in mice (senile osteoporosis mouse models).
“BT-BEVs-CS facilitated the osteogenic differentiation of BMSCs and ameliorated pathological bone loss in SOP mouse models.”
Animalssenile osteoporosis mouse modelsbone marrow mesenchymal stem cell
Engineered bacterial particles reduced bone loss in older mice
Journal of nanobiotechnology
Pathological bone loss
downin mice1
Dual-targeted bioengineered bacterial extracellular vesicles decrease pathological bone loss in mice (senile osteoporosis mouse models).
“BT-BEVs-CS facilitated the osteogenic differentiation of BMSCs and ameliorated pathological bone loss in SOP mouse models.”
Animalssenile osteoporosis mouse modelsbone
Engineered bacterial particles reduced bone loss in older mice
Journal of nanobiotechnology
Weekly injections for one month improved bone structure in 18-month-old male mice with age-related bone loss.Weekly injections for one month improved bone structure in 18-month-old male mice with age-related bone loss.